In clinical practice, the CCL5+ TAMs could be used to comprehensively evaluate the prognostic patterns as well as unique TME characteristics among individuals, allowing for the identification of different immunophenotypes and promotion of treatment efficiency for ccRCC. This evidence concerns the gene CCL5 and nonpapillary renal cell carcinoma.